GlassScriptPhysician profile
Stephen James Mularz
NPI 1982018156
$4,539.07
in general payments reported to CMS, 2019-2025
26 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $82.51 · 2021: $693 · 2022: $837 · 2023: $541 · 2024: $1,077 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,827 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,827.36 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,265.96 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $750.67 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $469.65 | 2021-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $469.22 | 2022-2025 | Livdelzi |
| Madrigal Pharmaceuticals | $330.56 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $225.78 | 2022-2025 | |
| La Jolla Pharmaceutical Company | $150.98 | 2023-2025 | Xacduro |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2024 | Andexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.87 | 2020-2025 | Xifaxan |
| Lilly USA, LLC | $87.87 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $76.13 | 2023-2025 | Voquezna |
| Endogastric Solutions, INC | $74.51 | 2023 | Esophyx |
| Pfizer INC. | $68.88 | 2020-2025 | |
| Ardelyx, INC. | $67.57 | 2024-2025 | Ibsrela |
| Echosens North America, INC. | $48.48 | 2022-2024 | Fibroscan |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $26.93 | 2021 | |
| Olympus America INC. | $23.82 | 2020 | |
| Aimmune Therapeutics, INC. | $22.76 | 2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $22.71 | 2021 | |
| Novo Nordisk INC | $22.70 | 2025 | Wegovy |
| Covidien LP | $17.51 | 2020 | |
| Ambu INC. | $17.33 | 2021 | |
| Intercept Pharmaceuticals, INC. | $16.35 | 2024 | |
| Alexion Pharmaceuticals, INC. | $14.46 | 2022 | |
| Merck Sharp & Dohme LLC | $13.74 | 2024 | Dificid |
| Boston Scientific Corporation | $13.63 | 2025 | Spyglass |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Mularz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.